115 related articles for article (PubMed ID: 15663294)
1. CYP1A2 in a smoking and a non-smoking population; correlation of urinary and salivary phenotypic ratios.
Woolridge H; Williams J; Cronin A; Evans N; Steventon GB
Drug Metabol Drug Interact; 2004; 20(4):247-61. PubMed ID: 15663294
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
Carrillo JA; Christensen M; Ramos SI; Alm C; Dahl ML; Benitez J; Bertilsson L
Ther Drug Monit; 2000 Aug; 22(4):409-17. PubMed ID: 10942180
[TBL] [Abstract][Full Text] [Related]
3. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
Hakooz NM
Curr Drug Metab; 2009 May; 10(4):329-38. PubMed ID: 19519341
[TBL] [Abstract][Full Text] [Related]
4. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
[TBL] [Abstract][Full Text] [Related]
5. Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity.
Sinués B; Fanlo A; Bernal ML; Mayayo E; Soriano MA; Martínez-Ballarin E
Ther Drug Monit; 2002 Dec; 24(6):715-21. PubMed ID: 12451287
[TBL] [Abstract][Full Text] [Related]
6. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
Fuhr U; Rost KL
Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690
[TBL] [Abstract][Full Text] [Related]
7. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.
Rasmussen BB; Brøsen K
Ther Drug Monit; 1996 Jun; 18(3):254-62. PubMed ID: 8738764
[TBL] [Abstract][Full Text] [Related]
8. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
Faber MS; Jetter A; Fuhr U
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH
Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of CYP1A2 and CYP2A6 activity: phenotypes and the effect of age and sex in a Nigerian population.
Adehin A; Bolaji OO
Drug Metab Pers Ther; 2015 Sep; 30(3):203-10. PubMed ID: 26098700
[TBL] [Abstract][Full Text] [Related]
11. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements.
Tang BK; Zhou Y; Kadar D; Kalow W
Pharmacogenetics; 1994 Jun; 4(3):117-24. PubMed ID: 7920691
[TBL] [Abstract][Full Text] [Related]
12. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.
Nakajima M; Yokoi T; Mizutani M; Shin S; Kadlubar FF; Kamataki T
Cancer Epidemiol Biomarkers Prev; 1994; 3(5):413-21. PubMed ID: 7920209
[TBL] [Abstract][Full Text] [Related]
13. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
Butler MA; Lang NP; Young JF; Caporaso NE; Vineis P; Hayes RB; Teitel CH; Massengill JP; Lawsen MF; Kadlubar FF
Pharmacogenetics; 1992 Jun; 2(3):116-27. PubMed ID: 1306111
[TBL] [Abstract][Full Text] [Related]
14. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.
Gunes A; Ozbey G; Vural EH; Uluoglu C; Scordo MG; Zengil H; Dahl ML
Pharmacogenomics; 2009 May; 10(5):769-78. PubMed ID: 19450128
[TBL] [Abstract][Full Text] [Related]
15. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment.
Rostami-Hodjegan A; Nurminen S; Jackson PR; Tucker GT
Pharmacogenetics; 1996 Apr; 6(2):121-49. PubMed ID: 9156692
[TBL] [Abstract][Full Text] [Related]
16. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia.
Bozikas VP; Papakosta M; Niopas I; Karavatos A; Mirtsou-Fidani V
Eur Neuropsychopharmacol; 2004 Jan; 14(1):39-44. PubMed ID: 14659985
[TBL] [Abstract][Full Text] [Related]
17. Establishing population distribution of drug-metabolizing enzyme activities for the use of salivary caffeine as a dynamic liver function marker in a Singaporean Chinese population.
Chia HY; Yau WP; Ho HK
Biopharm Drug Dispos; 2016 Apr; 37(3):168-81. PubMed ID: 26862045
[TBL] [Abstract][Full Text] [Related]
18. Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity.
Notarianni LJ; Oliver SE; Dobrocky P; Bennett PN; Silverman BW
Br J Clin Pharmacol; 1995 Jan; 39(1):65-9. PubMed ID: 7756101
[TBL] [Abstract][Full Text] [Related]
19. Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls.
Petersen MS; Halling J; Damkier P; Nielsen F; Grandjean P; Weihe P; Brøsen K
Eur J Clin Pharmacol; 2006 Dec; 62(12):1041-8. PubMed ID: 17089110
[TBL] [Abstract][Full Text] [Related]
20. Correlation between assessment of cytochrome P450 1A2 activity and enzyme activity scores, and their relation to clozapine exposure.
Alarcan H; Cannet P; Camus V; Fond G; Zendjidjian X; Guilhaumou R; Quaranta S
Br J Clin Pharmacol; 2023 May; 89(5):1665-1671. PubMed ID: 36507652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
